1
|
Qutob HMH, Saad RA, Bali H, Osailan A, Jaber J, Alzahrani E, Alyami J, Elsayed H, Alserihi R, Shaikhomar OA. Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Med Clin (Engl Ed) 2022; 159:569-574. [PMID: 36536624 PMCID: PMC9752094 DOI: 10.1016/j.medcle.2022.02.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 02/23/2022] [Indexed: 12/23/2022]
Abstract
BACKGROUND AND AIM The most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers. MATERIALS AND METHODS This study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients' lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab. RESULTS The WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 (p = 0.004 and p = 0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with p = 0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant (p = 0.002). CONCLUSION The study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.
Collapse
Affiliation(s)
- Haitham M H Qutob
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Rabigh, 25732, Saudi Arabia
- Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia
| | - Ramadan A Saad
- Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia
- Physiology Department, Faculty of Medicine, Ainshams University, Cairo, Egypt
| | - Hamza Bali
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Abdulaziz Osailan
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Jumana Jaber
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Emad Alzahrani
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Jamilah Alyami
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Hani Elsayed
- Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia
- Physics Department, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Raed Alserihi
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
- 3D Bioprinting Unit, Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Osama A Shaikhomar
- Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| |
Collapse
|
2
|
Qutob HM, Saad RA, Bali H, Osailan A, Jaber J, Alzahrani E, Alyami J, Elsayed H, Alserihi R, Shaikhomar OA. Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Med Clin (Barc) 2022; 159:569-574. [PMID: 35659421 PMCID: PMC9035366 DOI: 10.1016/j.medcli.2022.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 02/16/2022] [Accepted: 02/23/2022] [Indexed: 01/08/2023]
Abstract
BACKGROUND AND AIM The most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers. MATERIALS AND METHODS This study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients' lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab. RESULTS The WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 (p=0.004 and p=0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with p=0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant (p=0.002). CONCLUSION The study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.
Collapse
Affiliation(s)
- Haitham M.H. Qutob
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Rabigh, 25732, Saudi Arabia,Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia,Corresponding author
| | - Ramadan A. Saad
- Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia,Physiology Department, Faculty of Medicine, Ainshams University, Cairo, Egypt
| | - Hamza Bali
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Abdulaziz Osailan
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Jumana Jaber
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Emad Alzahrani
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Jamilah Alyami
- Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
| | - Hani Elsayed
- Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia,Physics Department, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Raed Alserihi
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia,3D Bioprinting Unit, Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Osama A. Shaikhomar
- Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| |
Collapse
|
3
|
Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterol Motil 2015; 27:1687-92. [PMID: 26598049 DOI: 10.1111/nmo.12726] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 10/14/2015] [Indexed: 02/08/2023]
Abstract
Magnetic resonance imaging of gastrointestinal (GI) function has advanced substantially in the last few years. The ability to obtain high resolution images of the undisturbed bowel with tunable tissue contrast and using no ionizing radiation are clear advantages, particularly for children and women of reproductive age. Barriers to diffusion in clinical practice so far include the need to demonstrate clinical value and the burden of data processing. Both difficulties are being addressed and the technique is providing novel insights into both upper and lower GI disorders of function at an ever increasing rate.
Collapse
Affiliation(s)
- J Alyami
- Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.,NIHR Nottingham Digestive Disease Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
| | - R C Spiller
- Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.,NIHR Nottingham Digestive Disease Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
| | - L Marciani
- Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.,NIHR Nottingham Digestive Disease Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
| |
Collapse
|